Together, our results demonstrate that (S)-VSP-77 can serve as a promising candidate for T2DM therapy and establish a rational foundation for designing specific drugs targeting PPARγ with advantages over current TZD drugs and representative partial agonist INT131. This evidence concerns the gene PPARG and type 2 diabetes mellitus.